PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.39
5.09M / 4.21M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.55%
Revenue growth 1.25-1.5x JHX's 4.79%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
-68.24%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-91.94%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-91.94%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
3.82%
Positive net income growth while JHX is negative. John Neff might see a big relative performance advantage.
2.17%
Positive EPS growth while JHX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.17%
Positive diluted EPS growth while JHX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.35%
Share count expansion well above JHX's 0.17%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.30%
Diluted share count expanding well above JHX's 0.89%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
333.98%
10Y revenue/share CAGR above 1.5x JHX's 62.05%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
110.69%
5Y revenue/share CAGR above 1.5x JHX's 62.05%. David Dodd would look for consistent product or market expansions fueling outperformance.
91.60%
3Y revenue/share CAGR 1.25-1.5x JHX's 79.48%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
328.52%
Similar net income/share CAGR to JHX's 332.10%. Walter Schloss would see parallel tailwinds or expansions for both firms.
244.12%
5Y net income/share CAGR at 50-75% of JHX's 332.10%. Martin Whitman might see a shortfall in operational efficiency or brand power.
270.44%
3Y net income/share CAGR above 1.5x JHX's 91.44%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
63.86%
5Y equity/share CAGR at 75-90% of JHX's 83.54%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
50.79%
3Y equity/share CAGR similar to JHX's 51.02%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.